Cargando…

Development and validation of monoclonal antibodies specific for Candida albicans Als2, Als9-1, and Als9-2

Fungal agglutinin-like sequence (Als) cell-surface glycoproteins, best characterized in Candida albicans, mediate adhesive and aggregative interactions with host cells, other microbes, and abiotic surfaces. Monoclonal antibodies (MAbs) specific for each C. albicans Als protein are valuable reagents...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Soon-Hwan, Coleman, David A., Zhao, Xiaomin, Hoyer, Lois L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9269773/
https://www.ncbi.nlm.nih.gov/pubmed/35802580
http://dx.doi.org/10.1371/journal.pone.0269681
_version_ 1784744303351824384
author Oh, Soon-Hwan
Coleman, David A.
Zhao, Xiaomin
Hoyer, Lois L.
author_facet Oh, Soon-Hwan
Coleman, David A.
Zhao, Xiaomin
Hoyer, Lois L.
author_sort Oh, Soon-Hwan
collection PubMed
description Fungal agglutinin-like sequence (Als) cell-surface glycoproteins, best characterized in Candida albicans, mediate adhesive and aggregative interactions with host cells, other microbes, and abiotic surfaces. Monoclonal antibodies (MAbs) specific for each C. albicans Als protein are valuable reagents for gaining insight into Als protein localization and function. This manuscript describes development and validation of MAbs specific for C. albicans Als2, as well as for C. albicans Als9-1 and Als9-2, two protein variants produced from the ALS9 locus. Native C. albicans ALS9 expression levels were not sufficiently high to produce detectable Als9 protein on the wild-type cell surface so MAb validation required production of overexpression strains, each featuring one of the two ALS9 alleles. An anti-Als2 MAb was raised against an N-glycosylated form of the protein immunogen, as well as an Endoglycosidase H-treated immunogen. The MAb raised against the N-glycosylated immunogen proved superior and immunolabeled C. albicans yeast cells and germ tubes, and the surface of Candida dubliniensis and Candida tropicalis yeasts. Als2 was visible on C. albicans yeast cells recovered from a murine model of oral candidiasis, demonstrating Als2 production both in vivo and in vitro. These new MAbs add to the collection of anti-Als MAbs that are powerful tools to better understand the role of Als proteins in C. albicans biology and pathogenesis.
format Online
Article
Text
id pubmed-9269773
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-92697732022-07-09 Development and validation of monoclonal antibodies specific for Candida albicans Als2, Als9-1, and Als9-2 Oh, Soon-Hwan Coleman, David A. Zhao, Xiaomin Hoyer, Lois L. PLoS One Research Article Fungal agglutinin-like sequence (Als) cell-surface glycoproteins, best characterized in Candida albicans, mediate adhesive and aggregative interactions with host cells, other microbes, and abiotic surfaces. Monoclonal antibodies (MAbs) specific for each C. albicans Als protein are valuable reagents for gaining insight into Als protein localization and function. This manuscript describes development and validation of MAbs specific for C. albicans Als2, as well as for C. albicans Als9-1 and Als9-2, two protein variants produced from the ALS9 locus. Native C. albicans ALS9 expression levels were not sufficiently high to produce detectable Als9 protein on the wild-type cell surface so MAb validation required production of overexpression strains, each featuring one of the two ALS9 alleles. An anti-Als2 MAb was raised against an N-glycosylated form of the protein immunogen, as well as an Endoglycosidase H-treated immunogen. The MAb raised against the N-glycosylated immunogen proved superior and immunolabeled C. albicans yeast cells and germ tubes, and the surface of Candida dubliniensis and Candida tropicalis yeasts. Als2 was visible on C. albicans yeast cells recovered from a murine model of oral candidiasis, demonstrating Als2 production both in vivo and in vitro. These new MAbs add to the collection of anti-Als MAbs that are powerful tools to better understand the role of Als proteins in C. albicans biology and pathogenesis. Public Library of Science 2022-07-08 /pmc/articles/PMC9269773/ /pubmed/35802580 http://dx.doi.org/10.1371/journal.pone.0269681 Text en © 2022 Oh et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Oh, Soon-Hwan
Coleman, David A.
Zhao, Xiaomin
Hoyer, Lois L.
Development and validation of monoclonal antibodies specific for Candida albicans Als2, Als9-1, and Als9-2
title Development and validation of monoclonal antibodies specific for Candida albicans Als2, Als9-1, and Als9-2
title_full Development and validation of monoclonal antibodies specific for Candida albicans Als2, Als9-1, and Als9-2
title_fullStr Development and validation of monoclonal antibodies specific for Candida albicans Als2, Als9-1, and Als9-2
title_full_unstemmed Development and validation of monoclonal antibodies specific for Candida albicans Als2, Als9-1, and Als9-2
title_short Development and validation of monoclonal antibodies specific for Candida albicans Als2, Als9-1, and Als9-2
title_sort development and validation of monoclonal antibodies specific for candida albicans als2, als9-1, and als9-2
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9269773/
https://www.ncbi.nlm.nih.gov/pubmed/35802580
http://dx.doi.org/10.1371/journal.pone.0269681
work_keys_str_mv AT ohsoonhwan developmentandvalidationofmonoclonalantibodiesspecificforcandidaalbicansals2als91andals92
AT colemandavida developmentandvalidationofmonoclonalantibodiesspecificforcandidaalbicansals2als91andals92
AT zhaoxiaomin developmentandvalidationofmonoclonalantibodiesspecificforcandidaalbicansals2als91andals92
AT hoyerloisl developmentandvalidationofmonoclonalantibodiesspecificforcandidaalbicansals2als91andals92